Old Web
English
Sign In
Acemap
>
Paper
>
Current Status and Optimal Management of Eculizumab Poor-Responders Due to C5 Polymorphisms
Current Status and Optimal Management of Eculizumab Poor-Responders Due to C5 Polymorphisms
2018
Yasutaka Ueda
Hiroyuki Takamori
Jun-Ho Jang
Chezi Ganzel
Saskia Langemeijer
Makiko Osato
Petra Muus
Jong Wook Lee
Jun-ichi Nishimura
Yuzuru Kanakura
Keywords:
Eculizumab
Intensive care medicine
Medicine
poor responder
optimal management
Immunology
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI
[]